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The Sympathetic Nervous System in Heart Failure
Physiology, Pathophysiology, and Clinical Implications
Filippos Triposkiadis, MD,* George Karayannis, MD,* Grigorios Giamouzis, MD,*‡
John Skoularigis, MD,* George Louridas, MD,† Javed Butler, MD, MPH‡
Larissa and Thessaloniki, Greece; and Atlanta, Georgia
Heart failure is a syndrome characterized initially by left ventricular dysfunction that triggers countermea-
sures aimed to restore cardiac output. These responses are compensatory at first but eventually become
part of the disease process itself leading to further worsening cardiac function. Among these responses is
the activation of the sympathetic nervous system (SNS) that provides inotropic support to the failing heart
increasing stroke volume, and peripheral vasoconstriction to maintain mean arterial perfusion pressure,
but eventually accelerates disease progression affecting survival. Activation of SNS has been attributed to
withdrawal of normal restraining influences and enhancement of excitatory inputs including changes in:
1) peripheral baroreceptor and chemoreceptor reflexes; 2) chemical mediators that control sympathetic out-
flow; and 3) central integratory sites. The interface between the sympathetic fibers and the cardiovascular
system is formed by the adrenergic receptors (ARs). Dysregulation of cardiac beta1-AR signaling and trans-
duction are key features of heart failure progression. In contrast, cardiac beta2-ARs and alpha1-ARs may
function in a compensatory fashion to maintain cardiac inotropy. Adrenergic receptor polymorphisms may
have an impact on the adaptive mechanisms, susceptibilities, and pharmacological responses of SNS. The
beta-AR blockers and the inhibitors of the renin-angiotensin-aldosterone axis form the mainstay of current
medical management of chronic heart failure. Conversely, central sympatholytics have proved harmful,
whereas sympathomimetic inotropes are still used in selected patients with hemodynamic instability. This
review summarizes the changes in SNS in heart failure and examines how modulation of SNS activity may
affect morbidity and mortality from this syndrome. (J Am Coll Cardiol 2009;54:1747–62) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.015t
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neart failure is a clinical syndrome that develops in response
o an insult resulting in a decline in the pumping capacity of
he heart. This is subsequently characterized by the contin-
ous interaction between the underlying myocardial dys-
unction and the compensatory neurohumoral mechanisms
hat are activated. Among many, these include the sympathetic
ervous system (SNS), the renin-angiotensin-aldosterone axis,
nd the cytokine system (1). These systems are initially able to
ompensate for the depressed myocardial function and preserve
ardiovascular homeostasis. However, their long-term activa-
ion has deleterious effects on cardiac structure and perfor-
ance, leading to cardiac decompensation and heart failure
rogression.
NS and Normal Cardiac Function
he SNS has a wide variety of cardiovascular actions,
ncluding heart rate acceleration, increase in cardiac con-
rom the *Department of Cardiology, Larissa University Hospital, Larissa, Greece;
Department of Cardiology, AHEPA University Hospital, Thessaloniki, Greece; and
he ‡Cardiology Division, Emory University, Atlanta, Georgia.v
Manuscript received February 24, 2009; revised manuscript received May 11, 2009,
ccepted May 14, 2009.ractility, reduction of venous capacitance, and constriction
f resistance vessels. On the contrary, the parasympathetic
ervous system affects the cardiovascular system by slowing
eart rate through vagal impulses (Fig. 1). The cardiac
ympathetic nerve fibers are located subepicardially and
ravel along the major coronary arteries representing the
redominant autonomic component in the ventricles. The
arasympathetic fibers run with the vagus nerve subendo-
ardially after it crosses the atrioventricular groove and are
ainly present in the atrial myocardium and less abundantly
n the ventricular myocardium (2). The ventricular sympa-
hetic innervation is characterized by a gradient from base to
pex (3). The cardiac neuronal system is made up of spatially
istributed cell stations comprising afferent, efferent, and in-
erconnecting neurons behaving as a control system (4). The
eurons are in constant communication with each other and
ach neuronal cell station is involved in cardio-cardiac reflexes
hat control spatially organized cardiac regions.
The sympathetic outflow to the heart and peripheral circu-
ation is regulated by cardiovascular reflexes. Afferent fibers are
sually carried toward the central nervous system by autonomic
erves, whereas efferent impulses travel from the central ner-
ous system toward different organs either in autonomic or
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responses originate from aortic
arch and carotid baroreceptors
(SNS inhibition), cardiopulmo-
nary baroreceptors (diverse reflexes
including the Bezold-Jarisch re-
flex, SNS inhibition), cardiovascu-
lar low-threshold polymodal re-
ceptors (SNS activation), and
peripheral chemoreceptors (SNS
activation) (5). The effect of SNS
activation on the periphery is me-
diated by 4 pathways (6): 1) nor-
epinephrine (NE) releasing neu-
rons through the right stellate
anglion reaching the sinus and atrioventricular nodes (result-
ng in an increase in heart rate and shortening of atrioventric-
lar conduction) and through the left stellate ganglion reaching
he left ventricle (resulting in an increase in contractile strength
nd blood pressure); 2) epinephrine (EPI), released in circula-
ion by the adrenal cortex affecting both the myocardium and
eripheral vessels; 3) direct effect on peripheral vessels through
ocal release of EPI and NE; and 4) circulating NE, which can
ct in multiple locations (e.g., increase in heart rate during
xercise of heart transplant recipients) (7).
ardiovascular Adrenergic Receptors (ARs)
he sympathetic transmitters NE and EPI bind to specific
Rs, which are specialized macromolecules embedded in the
ell membrane. Approximately 80% of NE released by the
ympathetic nerve terminals is recycled by the NE transporter
, whereas the remainder clears into circulation (8). Both NE
nd EPI exert their biological actions via activation of 9
ifferent AR subtypes, 3 alpha1-receptors (alpha1A, alpha1B,
nd alpha1D), 3 alpha2-receptors (alpha2A, alpha2B, and
lpha2C), and 3 beta-receptors (beta1, beta2, and beta3) (9). All
Rs have 7 transmembrane receptors that signal primarily via
nteraction with heterotrimeric G proteins.
The human heart contains beta1, beta2, and beta3 recep-
ors (10). The beta1- and beta2-AR subtypes are expressed
t a ratio of 70:30, and their stimulation increases cardiac
ontractility (positive inotropic effect), frequency (positive
hronotropic effect), and rate of relaxation (lusitropic effect)
s well as impulse conduction through the atrioventricular
ode (positive dromotropic effect). Beta3-ARs are predom-
nantly inactive during normal physiologic conditions
11); however, their stimulation seems to produce a
egative inotropic effect opposite to that induced by
eta1- and beta2-ARs, involving the nitric oxide synthase
athway (12), acting as a “safety valve” during intense
drenergic stimulation (13). Agonist-induced activation
f beta-ARs catalyzes the exchange of guanosine triphos-
hate for guanosine diphosphate on the Galpha-subunit of
proteins, resulting in the dissociation of the heterotri-
Abbreviations
and Acronyms
AR  adrenergic receptor
ATP  adenosine
triphosphate
cAMP  3=,5=-cyclic
monophosphate
EPI  epinephrine
MIBG 
metaiodobenzylguanidine
NE  norepinephrine
SNS  sympathetic
nervous systemer into active Galpha- and Gbeta-gamma-subunits, which cre competent to signal independently (14). The hetero-
eneity of G-protein alpha subunit, of which there are
20 subtypes (Gs, Gi, Gq, Go, and so on), is the central
asis of G-protein coupled receptor signaling.
In the human heart, activation of beta1- and beta2-ARs is
he most powerful physiologic mechanism to acutely in-
rease cardiac performance. Beta1-ARs activate Gs proteins
hereas beta2-ARs use both Gi and Gs proteins. Gs
ignaling acts as a “receptor-accelerator,” and Gi signaling as
“receptor-brake” (15). Gs signaling stimulates the effector
nzyme, adenyl cyclase, resulting in dissociation of adeno-
ine triphosphate (ATP) into the second messenger aden-
sine 3=,5=-cyclic monophosphate (cAMP), which in turn
inds to cAMP-dependent protein kinase A. Targets of
rotein kinase A-induced phosphorylations in the AR
ignaling pathway are: 1) the L-type calcium channels and
yanodine receptors, both leading to an increase in Ca2
ntry into the cell (16); 2) the hyperpolarization-activated
yclic nucleotide-gated channels, which generate the
yperpolarization-activated cation inward current (If) af-
ecting the initiation and modulation of rhythmic activity in
ardiac pacemaker cells (17); 3) phospholamban, a modu-
ator of the sarcoplasmic reticulum associated ATP-
ependent calcium pump, which accelerates Ca2 reuptake
y the sarcoplasmic reticulum accelerating cardiac relaxation
18); 4) troponin I and myosin binding protein-C, which
educe myofilament sensitivity to Ca2accelerating the re-
axation of myofilaments (18); and 5) phospholemman, a
ubunit of Na/K-ATPase, relieving its inhibitory influ-
nce and resulting in the stimulation of the sodium pump
19) (Fig. 2).
Moreover, protein kinase A phosphorylates beta-ARs,
esulting in partial uncoupling and desensitization of the
eceptor to further agonist stimulation (heterologous desensi-
ization). Gi signaling decreases cAMP levels, activates
itogen-activated protein kinase, and contributes to the
egulation of receptor signaling and activation of nuclear
ranscription.
The human heart also expresses alpha1A- and alpha1B-
Rs at lower levels (20%) than those of beta-ARs (20). It
s unknown whether cardiac alpha1-ARs play a major role
nder physiologic conditions. Moreover, the alpha1-ARs
eavily populate major arteries (including the aorta, pulmo-
ary arteries, mesenteric vessels, and coronary arteries) and
ctivation of these receptors by NE and EPI is a major
ontributor to the regulation of blood flow by vasoconstric-
ion (21). Both alpha1A- and alpha1B-AR subtypes couple to
he Gq family of heterotrimeric G proteins, which, in turn,
ctivate phospholipase Cb. Phospholipase Cb hydrolyzes
hosphatidylinositol (4,5) bisphosphate to generate the
econd messengers inositol [1,4,5]-trisphosphate and
-diacylglycerol. Inositol [1,4,5]-trisphosphate contributes
o the regulation of intracellular Ca2 responses, whereas
-diacylglycerol activates some of the isomers of protein
inase C as well as some of the transient receptor potential
hannels (Fig. 3). Stimulation of vascular alpha2B-ARs
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November 3, 2009:1747–62 Sympathetic Nervous System in Heart Failureauses a transient vasoconstriction, whereas activation of
entral alpha2A-ARs leads to a decrease in blood pressure by
nhibiting central sympathetic outflow (22). The release of
E from sympathetic nerves is controlled by pre-synaptic
lpha2A- and alpha2C-ARs. Both pre-synaptic alpha2-ARs
re essential, as deletion of alpha2A- and alpha2C-ARs leads
o cardiac hypertrophy and failure due to chronically en-
anced catecholamine release.
ssessment of SNS Activity
ctivity of SNS is difficult to evaluate in the clinical setting.
lasma NE measurement represents a crude guide to assess
Heart
Paravertebral
ganglia
Vessels Postganglionic
sympathetic
efferents
Postganglionic
neurons
Adrenal
Prevertebral
ganglia Preganglionic
sympathetic
efferents
EPI
Figure 1 The Sympathetic Nervous System
The most important level of integration of sympathetic nervous system efferen
tion of the medulla. The hypothalamus modifies the activity of the medullary ce
stress. The motor outflow of the sympathetic nervous system is formed by 2 s
in the brain stem or the spinal cord, and the second set (post-ganglionic neuro
pathetic ganglia. The sympathetic pre-ganglionic neurons originate in the latera
(thoracolumbar outflow). The axons of these neurons (short, myelinated) exit th
cells or chromaffin cells in the adrenal gland that release epinephrine (EPI). Th
(3 in the cervical region including the right and left stellate ganglia, 10 to 11 i
unpaired ganglion lying in front of the coccyx), which lie on each side of the ve
vertebral (pre-aortic), which provide axons that are distributed with the 3 major
of the sympathetic pre-ganglionic neurons is acetylcholine, whereas the predom
rine. Sympathetic activity is attenuated (–) by the arterial baroreflex and the ca
(CSAR) and the arterial chemoreceptor reflex. H  hypothalamus; M  medullaympathetic neural function because it depends on the rate mf immediate NE reuptake as well as NE clearance from
irculation (23). Likewise, frequency analysis of heart rate
ariability signals, although easily performed noninvasively,
as been shown to have limitations (24). Indeed the
ow-frequency spectral power (approximately 0.05 to 0.15
z), in addition to cardiac sympathetic nerve traffic, de-
ends on other factors, including multiple neural reflexes,
ardiac AR sensitivity, post-synaptic signal transduction,
nd electrochemical coupling (25). Two state-of-the-art
echniques that best quantify sympathetic nerve activity in
umans are radiotracer measurements of regional NE spill-
ver and microneurography (microelectrode direct measure-
( )
M
H
• Arterial baroreflex
• Cardiopulmonary reflex
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-
• CSAR 
• Arterial chemoreflex
Spinal cord
Preganglionic
neurons
ities to the cardiovascular system resides in the dorsolateral reticular forma-
and is important in stimulating cardiovascular responses to emotion and
connected sets of neurons. The first set (pre-ganglionic neurons) originates
s outside the central nervous system in collections of nerve cells called sym-
s of the 12 thoracic and the first 2 or 3 lumbar segments of the spinal cord
al cord in the ventral roots and then synapse on either sympathetic ganglion
pathetic ganglia can be divided into 2 major groups: 1) the paravertebral
horacic region, 4 in the lumbar region, 4 in the sacral region, and a single,
e and are connected to form the sympathetic chain or trunk; and 2) the pre-
ointestinal arteries arising from the aorta. The predominant neurotransmitter
neurotransmitter of most sympathetic post-ganglionic neurons is norepineph-
lmonary reflex and increased () by the cardiac sympathetic afferent reflext activ
nters
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Sympathetic Nervous System in Heart Failure November 3, 2009:1747–62roximate neural stimulus to NE release) (26,27). These
ssessments allow discrimination between the central or
eripheral contribution of increased plasma NE levels and
recise estimation of the regional sympathetic neural func-
ion, both under physiological and pathological conditions.
Neural imaging techniques allow direct visualization of
ympathetic innervation of human organs, thus providing
nformation on the in vivo metabolism of NE in different
ardiovascular beds. Cardiac neuronal distribution and func-
ion can be imaged with standard gamma-cameras and
ositron emission tomography using radiolabeled analogs of
E (28); whereas, post-synaptic beta-AR distribution and
ensity can be determined using positron emission tomog-
aphy (29). Although technical improvements have allowed
or a more precise assessment of human adrenergic function,
o technique so far available can be viewed as the “gold
tandard” (30). Limitations of the various techniques may be
educed if these methods are seen as being complementary
nd are employed in combination.
Cardiac sympathetic neuronal activity or its pharmaceutical
β-AR LTCC
Ca+
+G
β AC
s
-G i ATP cAMP
C ++a
MyBPCTnI
Sarcomere
α
α
γ
Figure 2 Beta-AR Signaling
The major intracellular effect of the sympathetic transmitters norepinephrine and e
increases the activity of the cAMP-dependent protein kinase A (PKA). PKA mediate
Ca channels (LTTC), hyperpolarization-activated cyclic nucleotide-gated (HCN) ch
proteins troponin I (TnI), cardiac myosin-binding protein C (MyBPC), and phosphole
triphosphate; CNBD  cyclic nucleotide-binding domain; Galpha-i and Galpha-s  G pnhibition can also be noninvasively assessed by the use of a23I-metaiodobenzylguanidine (MIBG), an analogue of NE
31), using semiquantitative analyses, namely early heart-to-
ediastinum ratio, late heart-to-mediastinum ratio, and myo-
ardial washout. Beta-blockade and renin-angiotensin-
ldosterone inhibition are associated with an increase in 123I-
IBG uptake and a reduced washout. Data from a systematic
eta-analysis suggest that patients with decreased late
eart-to-mediastinum or increased myocardial 123I-MIBG
ashout have a worse prognosis than those patients with
ormal semiquantitative myocardial MIBG parameters
32). A prospective study that compared the predictive value
f cardiac 123I-MIBG imaging for sudden cardiac death
ith that of the signal-averaged electrocardiogram, heart
ate variability, and QT dispersion in patients with mild-
o-moderate heart failure demonstrated that 123I-MIBG
as the only powerful predictor of sudden cardiac death
ndependently of left ventricular ejection fraction (33).
inally, the recently presented ADMIRE-HF (AdreView
yocardial Imaging for Risk Evaluation in Heart Failure)
rial demonstrated that 123I-MIBG cardiac imaging carries
HCN
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ries of phosphorylations in diverse intracellular substrates, including the L-type
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(PLM). AC  adenylyl cyclase; AR  adrenergic receptor; ATP  adenosine
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November 3, 2009:1747–62 Sympathetic Nervous System in Heart Failuretratifying heart failure patients on top of commonly used
arkers such as left ventricular ejection fraction and B-type
atriuretic peptide (34).
eart Failure and SNS Hyperactivity
yocardial systolic dysfunction is associated with neuro-
umoral hyperactivity aiming at preservation of cardiac
utput. The neuronal limb of this response is represented
y SNS, whereas the humoral limb is represented by the
ncreased secretion of certain hormones, the most impor-
ant being those forming the renin-angiotensin-
ldosterone axis (35). Sympathetic hyperactivity is evi-
enced by increased plasma NE levels, central
ympathetic outflow, and NE plasma spillover from
ctivated sympathetic nerve fibers (36). Indeed, applica-
ion of isotope dilution methods for measuring cardiac
E plasma release indicate that in untreated heart failure
atients, cardiac NE spillover is increased as much as
0-fold, similar to levels seen in healthy hearts during
Trp
PLCb
PIP
Gq
γ
β
Ca++ 2IP3+DAG
PKC
Calcineurin?
Sarcomere
Figure 3 Alpha1-AR Signaling
Agonist-induced stimulation of alpha1-ARs activates Gq and phospholipase Cb (PLC
tol trisphosphate (IP3) and diacylglycerol (DAG). DAG, in turn, activates protein kina
induce transcriptional changes. Moreover, IP3 interacts with perinuclear inositol tri
and DAG increase the permeability of the transient receptor potential (Trp) channe
signaling pathways. Ca2 entry through transient receptor potential channels may
tivates epithelial growth factor receptors, resulting in formation of phosphoinositid
pathway, and initiation of cell-survival signaling pathways. Abbreviations as in Figuaximal exercise (37). There is limited information cegarding chronic SNS activation in heart failure with
reserved left ventricular ejection fraction (diastolic heart
ailure) (38). However, the findings of a recent study
ndicate that, in patients with hypertension, SNS hyper-
ctivity (increased muscle sympathetic nerve traffic) may
ontribute to the development of left ventricular diastolic
ysfunction and account for the increased cardiovascular
isk (39).
In contrast to the increased muscle sympathetic nerve
ctivity and NE spillover, patients with systolic heart failure
ay have decreased neuronal density, decreased neuronal
unction resulting in decreased NE concentration within the
ardiomyocytes, or a combination, besides a reduction in
ost-synaptic beta-receptor density (40). The mechanism
or decreased intracellular NE concentration is unclear.
xperimental studies suggest reduced neuronal NE trans-
orter expression and/or activity in association with height-
ned release (41). Moreover, complementary animal and
uman studies demonstrated a reduction in the myocardial
α-AR
PIP2 PIP3
PI3K?
AKT
Cell protection pathways
Transcription factors
Protein synthesis
ulting in hydrolysis of phosphatidylinositol bisphosphate (PIP2), to generate inosi-
(PKC) to initiate a series of phosphorylations that alter channel activity and
phate receptors (IP3R) disinhibiting growth-related gene transcription. Both PIP2
2, which enters the cell and activates calcineurin to initiate downstream growth
ct on myofilaments enhancing contractile responses. The alpha1-AR also transac-
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Sympathetic Nervous System in Heart Failure November 3, 2009:1747–62eart failure, which in turn modifies the expression of NE
ransporter in cell culture models (42).
echanisms of SNS hyperactivity in heart failure. The
ympathetic hyperactivity observed in heart failure is closely
elated to abnormalities in cardiovascular reflexes. The
ympathoinhibitory cardiovascular reflexes such as the arte-
ial baroreceptor reflex are significantly suppressed, whereas
he sympathoexcitatory reflexes, including the cardiac sym-
athetic afferent reflex and the arterial chemoreceptor reflex,
re augmented (43). Moreover, in heart failure, the cardiac
euronal hierarchy undergoes remodeling and the spatially
rganized reflexes acting in isolation may destabilize efferent
euronal control of regional cardiac electrical and/or me-
hanical events. Also, the central nervous system may
eceive input from a variety of sources in the body and
ctivate mechanisms that play a major role in progressive
ardiac remodeling and dysfunction (Fig. 4) (44,45). For
xample, it has been demonstrated that the angiotensin-II
nd aldosterone produced locally in the brain affect SNS
ctivation and progression of systolic heart failure (46,47). It
eems that angiotensin-II initiates a positive feedback
echanism leading to up-regulation of the angiotensin II
ype 1 receptor, nitric oxide inhibition, and increased
roduction of superoxide anion through the action of reduced
icotinamide adenine dinucleotide phosphate oxidase, lead-
RAAS
Cytokine
Excitatory
reflexes (2)
Inhibitory
reflexes
(1)Insult
Figure 4 Sympathetic Activation in Systolic Heart Failure
(1) An insult causes cardiac dysfunction and decreases cardiac output. (2) Att
tatory sympathetic cardiovascular reflexes is associated with increased sympat
mented cardiovascular sympathetic afferent reflex mediated by an increase in
increases in sympathetic output. (5) The chronic increase in sympathetic outp
the interstitium leading to left ventricular (LV) dilation and systolic dysfunctionng to increased sympathetic outflow and disease progres-
ion (48,49).
NS hyperactivity and cardiac ARs. Prolonged SNS
ctivation adversely affects excitation-contraction cou-
ling (50) and enhances apoptotic pathways (51), playing
central role in the progression of chronic heart failure.
striking feature of heart failure is a characteristic set of
olecular alterations in the components of the beta-AR
ignaling pathway, including a decrease in beta1-AR
ensity and messenger ribonucleic acid, uncoupling of
eta1-AR from Gs, increased Gi protein and messenger
ibonucleic acid, and impaired compartmentalization of
AMP/protein kinase A signaling (52–54). Beta1-AR
bnormalities have been attributed to the recruitment of
oth beta-AR kinase 1 and phosphoinositide 3-kinase to
he ligand-activated receptor complex (55,56). In addi-
ion, the levels of both Gi signaling proteins and the
-protein receptor kinases are increased. It seems that
eta-AR desensitization is a predominantly protective
daptation, which follows the increase in NE plasma
evels that keeps intracellular cAMP concentration con-
tant (57). This is further supported by the fact that
verexpression of human beta1-ARs in transgenic mice
nitially augments cardiac function but eventually leads to
athologic hypertrophy and heart failure (58).
NO
(3)
(4)
(5)
LV Remodeling
on of inhibitory sympathetic cardiovascular reflexes and augmentation of exci-
input in the central nervous system. (3 and 4) Central facilitation of the aug-
ensin II and cytokines and a decrease in nitric oxide (NO) contributes to tonic
ssociated with structural and functional changes in the cardiomyocytes and
modeling). m  medulla; RAAS  renin-angiotensin-aldosterone system.s
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November 3, 2009:1747–62 Sympathetic Nervous System in Heart FailureThe role of beta2-ARs in heart failure has not been
elineated clearly. There is no significant change in the
evels of beta2-ARs in the failing heart, and studies in
ransgenic animals have demonstrated that, in contrast to
he early cardiomyopathy resulting from low-level (5-fold)
ardiac overexpression of beta1-ARs, even a 100-fold over-
xpression of beta2-ARs in the mouse heart significantly
ncreases cardiac contractile force without any cardiomyop-
thic consequences; extremely higher levels of overexpres-
ion (up to 350-fold) are needed to induce pathological
hanges (59). Moreover, because beta2-AR signaling con-
ributes to an increase in the levels of Gi, it has been
uggested that this may activate a protective antiapoptotic
athway in the setting of catecholamine excess. Indeed, in a
ecent experimental study, selective inhibition of Gi-
ignaling in response to myocardial ischemia was associated
ith a marked enhancement of myocardial infarct size and
poptotic signaling (60). The role of beta3-ARs in heart
ailure has not been elucidated. However, it has been
roposed that in heart failure there is an excess of beta3-AR
ignaling, which exerts a negative inotropic effect by increas-
ng nitric oxide production and inhibiting calcium transients
61,62).
Alpha1-ARs may function in a compensatory fashion to
aintain cardiac inotropy in the heart involved in both
evelopmental cardiomyocyte growth as well as pathological
ypertrophy (63). In the presence of pressure overload or
ith myocardial infarction, activation of alpha1-ARs, par-
icularly the alpha1A-subtype, also appears to produce im-
ortant pro-survival effects at the level of the cardiomyocyte
nd to protect against maladaptive cardiac remodeling and
ecompensation to heart failure (64,65). Recent evidence
uggests that alpha2-AR deficiency is associated with ele-
ated catecholamine levels, cardiac hypertrophy, fibrosis,
nd eventually heart failure (66).
atecholamine cardiotoxicity. Catecholamine-induced
ardiotoxicity is well known. Intravenous infusions of iso-
roterenol or NE result in acute contraction band lesions
ttributed to relative hypoxia, increased sarcolemmal per-
eability, calcium overload, elevation of cAMP, activation
f alpha-ARs, activation of beta-ARs, and formation of
xidative catecholamine metabolites (67,68). Chronic cate-
holamine administration in rats causes interstitial fibrosis,
educes beta-AR–mediated inotropic responses, promotes
yocyte apoptosis, and induces pump dysfunction primarily
hrough left ventricular dilation (69,70). Moreover, expo-
ure to NE of both adult and neonatal rat cardiac myocytes
timulates apoptosis via the adrenergic and the reactive
xygen species–tumor necrosis factor–caspase signaling
athways (71,72). Of note, catecholamines may induce
xidative damage through reactive intermediates resulting
rom their auto-oxidation, irrespective of their interaction
ith ARs, thus representing an important factor in the
athogenesis of catecholamine-induced cardiotoxicity (73).
Catecholamine surge has been implicated in the patho-enesis of stress (Takotsubo) cardiomyopathy or apical pallooning (74). It has been hypothesized that stress cardio-
yopathy is a form of myocardial stunning, produced by the
igh levels of circulating EPI, which trigger a negative
notropic switch in intracellular signal trafficking in ventric-
lar cardiomyocytes, from Gs protein to Gi protein signaling
ia the beta2-AR (75). This effect is magnified at the apical
yocardium, where beta-AR density is greatest (76).
R Polymorphisms
arked variability in disease phenotype and response to
reatment suggests a potential disease-modifying role for
ommon genetic variants in heart failure. Functional poly-
orphisms in beta- and alpha-AR genes, which have been
ssociated with heart failure phenotypes and interaction
ith beta-blockers, are under pharmacogenomics, the study
f variations of deoxyribonucleic acid and ribonucleic acid
haracteristics as related to drug response, and pharmaco-
enetics investigations. Common polymorphisms of the
eta1-ARs are: 1) the arginine to glycine switch at codon
89 (Arg389Gly), associated with significantly lower
denylyl cyclase activity in response to agonist than the
rg389 variant (77); and 2) the serine to glycine switch at
odon 49 (Ser49Gly), associated with increased agonist-
romoted down-regulation and adrenergic coupling than
he Ser49 variant (78). Likewise, common polymor-
hisms of the beta2-ARs are: 1) the glycine to arginine
witch at codon 16 (Gly16Arg), resulting in reduced
gonist-promoted down-regulation (79); 2) the glutamine
o glutamic acid switch at codon 27 (Gln27Glu), which is
ore resistant to receptor down-regulation; and 3) the threo-
ine to isoleucine switch at codon 164 (Thr164Ile), demon-
trating impaired receptor coupling and reduced adenylyl
yclase activation (80). Finally, a deletion mutation of amino
cids 322 to 325 (alpha2Cdel322-325) in alpha2-AR gene leads
o increased NE release (81).
A lower prevalence of ventricular arrhythmias has been
ttributed to the Gly389 allele (82) and improved survival
as been reported for African-American heart failure
atients with the G-protein receptor kinase 5–Leu41
ariant (83).
herapeutic impact of beta-AR polymorphisms. Many
tudies have examined the impact of the aforementioned
olymorphisms in response to beta-blockade among heart
ailure patients. Preliminary studies in patients treated with
arious beta-blockers have demonstrated a survival benefit
84) and a significant reduction in left ventricular end-
iastolic diameter (85) for those who carried the Gly49
llele as compared to the Ser49 homozygous patients. A
imilar reversal of the remodeling process has been reported
or Arg389-homozygous heart failure patients treated with
arvedilol as compared with Gly389-homozygous (86) and
rg389Gly-heterozygous patients (87). However, neutral
esults have also been reported. For example, no survival
enefit was observed for the Ser49Gly or the Arg389Gly
atients treated with carvedilol (79,88), bisoprolol (79), or
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ly389 patients treated with metoprolol CR/XL (89).
inally, a dose-dependent response to beta-blockade has
een reported, whereby low doses in patients carrying the
ly49 allele portend worse outcomes than in Ser49-
omozygous patients, whereas in higher doses, genotype-
ependent differences are not observed (90).
More recent data, however, suggest improvement in the
herapeutic effect of bucindolol by pharmacogenetic target-
ng. In the deoxyribonucleic acid substudy of the BEST
Beta Blocker Evaluation of Survival Trial) (91), patients
arrying the Arg389 genotype had a greater agonist-
romoted ventricular contractility and improved age-, sex-,
nd race-adjusted survival than the Gly389 carriers (92).
ombinations of the beta1-AR (codon 389 Arg¡Gly) and
lpha2C-AR (322-325 WT¡del) polymorphisms were re-
ently used to stratify patients according to the clinical
esponse to bucindolol into “very favorable,” “favorable,” and
unfavorable” genotypes (Table 1) (93). Finally, a combina-
ion of 3 genetic polymorphisms (the Arg389 allele in-
luded) acted as a predictor of appropriate shock therapies
n patients with and without heart failure carrying an
mplantable cardioverter-defibrillator, thus identifying those
t high risk for sudden cardiac death (94). In this respect,
he use of genetic polymorphisms as potential tools to guide
herapeutic strategies seems a promising new approach.
herapeutic Implications
nhibition of SNS activity. BETA-BLOCKERS. Beta-blockers
an be broadly classified into generations: 1) first generation,
hich are nonselective and competitively block both the
eta1- and beta2-AR (propranolol, nadolol, timolol); 2) sec-
nd generation, with much higher affinity for the beta1- than
or the beta2-AR (atenolol, metoprolol, bisoprolol); and 3)
hird generation, which may be selective (celiprolol, nebivo-
ol) or nonselective (bucindolol, carvedilol, labetalol) but all
ause peripheral vasodilation mediated via alpha1-AR
lockade (bucindolol, carvedilol, labetalol), beta2-AR ago-
ism (celiprolol), or nitric oxide synthesis (nebivolol) (95).
ardioselectivity of beta-blockers is dose-dependent and
ecreases with larger doses. Both selective and nonselective
gents have negative chronotropic and inotropic effects.
elective agents have a less inhibitory affect on the beta2-
eceptors and are less likely to cause peripheral vasoconstric-
ion (96). Exercise performance may be impaired to a lesser
xtent by beta1-selective agents, partially because beta2-
utcomes by Beta1 and Alpha2C Genotype in the BEST Genetic SubTable 1 Outcomes by Beta1 and Alpha2C Genotype in the BEST
End Point
Beta1389Arg/Arg 
Alpha2C322-325 WT or DEL Carrier
(n  493)
All-cause mortality 0.62 (0.39–0.99)*
Cardiovascular mortality 0.52 (0.31–0.88)*
Heart failure hospitalization 0.56 (0.39–0.82)†ata presented as relative risk (95% confidence interval). *p  0.05; †p  0.01.
Arg  arginine; BEST  Beta-Blocker Evaluation of Survival Trial; DEL  deletion; Gly  glycine; WT lockade tends to blunt the exercise-induced increase in
keletal muscle blood flow. Finally, there are beta-blockers
hat at low concentrations antagonize the cardiostimulant
ffects of catecholamines but at high concentrations cause
ardiostimulation. These cardiostimulant beta-blockers
e.g., pindolol, alprenolol, oxprenolol), widely known as
onconventional partial agonists, antagonize the effects of
atecholamines through a high-affinity site (beta1HAR), but
ause cardiostimulation mainly through a low-affinity site
beta1LAR) of the myocardial beta1-R (97). Nonconven-
ional partial agonists are considered potentially arrhythmo-
enic and should not be used for heart failure treatment.
The majority of beta-blockers are partially or totally
etabolized by CYP2D6, whose gene has more than 90
ifferent variants (98). Individuals homozygous for non-
unctional alleles are considered poor metabolizers. Several
nconsistencies have been reported regarding the genotype-
henotype correlations for intermediate or extensive me-
abolizers (99). Poor metabolizers treated with metoprolol
ave a 5-fold higher risk for adverse effects (100), whereas
he adverse effects of carvedilol and bisoprolol are less
nfluenced by the genetic background (101,102).
Among all beta-blockers, bisoprolol (except in U.S.),
arvedilol, and metoprolol succinate (except in Canada) are
lmost universally approved for the treatment of chronic
eart failure (Table 2) (103–114). Chronic beta-blocker
herapy improves left ventricular performance and reverses
eft ventricular remodeling, reduces risk of hospitalization,
nd improves survival. Various protective mechanisms
inked with SNS antagonism have been attributed to
eta-blockers, namely: 1) inhibition of catecholamine car-
iotoxic effects; 2) beta1-AR up-regulation (carvedilol is an
xception); 3) attenuation of neurohumoral vasoconstric-
ive, growth-promoting, and pro-apoptotic systems (renin-
ngiotensin-aldosterone system, endothelin); 4) subendo-
ardial coronary flow enhancement (as a result of diastolic
rolongation); 5) restoration of the reflex control on the
eart and circulation; and 6) improved myocardial perfor-
ance (by reducing heart rate and oxygen demand) (115).
LPHA-BLOCKERS. In the Veterans Administration Co-
perative Study (116), heart failure patients receiving the
lpha1-blocker prazosin experienced worse outcomes
han did those receiving the combined vasodilator ther-
py of hydralazine and isosorbide dinitrate. Prazosin
hronic use has been reported to increase catecholamine
yetic Substudy
Beta1389Gly Carrier 
Alpha2C322-325 WT/WT
(n  413)
Beta1389Gly Carrier 
Alpha2C322-325 DEL Carrier
(n  134)
0.75 (0.48–1.17) 1.04 (0.43–2.54)
0.60 (0.36–0.97)* 1.11 (0.45–2.78)
0.77 (0.53–1.13) 0.73 (0.35–1.53)studGenwild type.
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iated through inhibition of the alpha1-receptor (117). In
he ALLHAT (Antihypertensive and Lipid-Lowering
reatment to Prevent Heart Attack Trial) study (118).
he doxazosin arm was terminated early because of the
igher heart failure incidence.
entrally acting agents. Central alpha2-Rs are possible
argets of treatment, because their excitation inhibits SNS
ctivation (119). Clonidine is a centrally acting agent with
arge Randomized Trials With Beta-Blockers and the ACC/AHA GuTable 2 Large Randomized Trials With Beta-Blockers and the A
Beta-Blocker Trial(s) Year n
Metoprolol MDC (104) 1993 383 All-
Metoprolol CR/XL MERIT-HF (105) 1999 3,991 All-
Carvedilol U.S. Carvedilol HF Study
Group (106)
1996 1,094 All-
Australia/New Zealand HF
Research Collaborative
Group (107)
1997 415 All-
CAPRICORN (108) 2001 1,959 All-
COPERNICUS (109) 2001 2,289 Car
COMET (110) 2003 3,029 All-
Bisoprolol CIBIS (111) 1994 641 All-
CIBIS II (112) 1999 2,647 All-
CIBIS III (113) 2005 1,010 Thi
Nebivolol* SENIORS (114) 2005 2,128 All-
Not endorsed in the ACC/AHA 2005 heart failure guidelines.
ACC/AHA  American College of Cardiology/American Heart Association; CAPRICORN  Carv
IBIS  Cardiac Insufficiency Bisoprolol Study; COMET  Carvedilol or Metoprolol European Trial; C
atio; LVEF  left ventricular ejection fraction; MDC  Metoprolol in Dilated Cardiomyopathy; MER
f the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Flpha2-agonist actions. In modest doses, it significantly cttenuates cardiac and renal sympathetic tone in heart
ailure patients. Interestingly, chronic clonidine administra-
ion exerts marked sympathoinhibitory effects without fur-
her clinical deterioration (120). Large clinical trials, how-
ver, are needed to evaluate the prospective of its broader
se in chronic heart failure.
The centrally acting sympatholytic agent moxonidine has
lso been used in heart failure patients. Moxonidine acts
hrough both alpha2 and imidazoline receptors (121,122). It
es Recommended DosesHA Guidelines Recommended Doses
Benefit
Initial Daily
Dose(s) (103)
Maximum
Dose(s)
mortality or morbidity was 34% lower
metoprolol than in the placebo group
66; 95% CI: 0.62 to 1.06; p  0.058).
ange in LVEF from baseline to
nths was significantly greater with
rolol than with placebo (0.13 vs. 0.06;
0001)
5–10 mg twice 100 mg twice
mortality was 34% lower in the
rolol CR/XL group than in the
o group (7.2% vs. 11.0%; HR: 0.66;
I: 0.53 to 0.81; p  0.00009)
12.5–25 mg once 200 mg once
mortality was 65% lower in the
ilol than in the placebo group
. 7.8%; HR: 0.65; 95% CI: 0.39 to 0.80;
01)
3.125 mg twice 25 mg twice
mortality or morbidity was 26% lower
carvedilol than in the placebo group
. 131; HR: 0.74; 95% CI: 0.57 to 0.95)
mortality was lower in the carvedilol
the placebo group (12% vs. 15%;
7; 95% CI: 0.60 to 0.98; p  0.03)
l reduced the combined risk of death
italization for a cardiovascular
by 27% (p  0.00002) and the
ed risk of death or HF hospitalization
(p  0.000004)
mortality was lower in the carvedilol
the metoprolol group (34% vs. 40%;
3; 95% CI: 0.74 to 0.93; p  0.0017)
mortality did not reach statistical
ance: 67 patients died on placebo,
bisoprolol (HR: 0.80; 95% CI: 0.56 to
 0.22). Bisoprolol reduced HF
lization (p  0.01) and improved the
nal status
mortality was 34% lower with
lol than on placebo (11.8% vs.
; HR: 0.66; 95% CI: 0.54 to 0.81;
0001)
1.25 mg once 10 mg once
demonstrated that it may be as safe
ficacious to initiate treatment for CHF
soprolol as with enalapril
mortality or cardiovascular hospital
ion occurred in 332 patients (31.1%)
ivolol compared with 375 (35.3%) on
o (HR: 0.86; 95% CI: 0.74 to 0.99;
039)
1.25 mg once 10 mg once
ost-Infarct Survival Controlled Evaluation; CHF  chronic heart failure; CI  confidence interval;
ICUS  Carvedilol Prospective Randomized Cumulative Survival; HF  heart failure; HR  hazard
Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; SENIORS  StudyidelinCC/A
cause
in the
(HR: 0.
The ch
12 mo
metop
p  0.
cause
metop
placeb
95% C
cause
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(3.2 vs
p  0.0
cause
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(104 vs
cause
than in
HR: 0.7
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or hosp
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by 31%
cause
than in
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cause
signific
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cause
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17.3%
p  0.
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IT-HF auses a marked dose-related reduction in plasma NE (123),
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n clinical trials, it led to increased mortality (124). Most
ikely, the harmful effects of sympatholysis are observed in
emodynamically unstable heart failure patients, who may
eed the adrenergic drive and, therefore, are pre-disposed to
he adverse effects of adrenergic withdrawal (125). Beta-R
nhibition can be easily reversed by NE competition, which
llows recruit adrenergic drive when needed to support
ardiac function.
enin-angiotensin-aldosterone system modulating
gents. The renin-angiotensin-aldosterone system is acti-
ated in heart failure and the degree of activation correlates
ith prognosis. Angiotensin-II and aldosterone production
nhances the release and inhibits the uptake of NE at nerve
ndings (126,127). Angiotensin-converting enzyme inhibitors
ave a predictable effect in increasing plasma renin and
ecreasing angiotensin-II and aldosterone levels, whereas
E and vasopressin reduction is attributed to the hemody-
amic improvement (128). Plasma aldosterone levels may be
levated as high as 20-fold in patients with heart failure,
rimarily due to increased production by the adrenal glands
ollowing stimulation by the high plasma angiotensin-II
oncentrations. In addition to its electrolyte and metabolic
ffects, aldosterone promotes the development of myocar-
ial fibrosis, facilitating the remodeling process and disease
rogression. Besides decreasing NE uptake, aldosterone has
negative effect on endothelial function and increases
lasminogen activator inhibitor-1 levels. Two trials have
hown benefit with aldosterone antagonists in heart failure
atients and may be partially related to their effect on NE
129,130).
NS stimulation. Dobutamine and milrinone represent
he most commonly used inotropes targeting increase in
AMP levels (131). Dobutamine stimulates cAMP produc-
ion by adenylate cyclase through the beta-adrenergic path-
ay, whereas the phosphodiesterase inhibitor milrinone
revents cAMP breakdown. Increased intracellular cAMP
eads to an increase in endomyocyte calcium release. Ele-
ated calcium levels enhance cardiac contractility through
ptimizing actin-myosin binding. However, increased cal-
ium levels are also responsible for inotropic therapy side
ffects, especially arrhythmogenesis. Both inotropes produce
vasodilatory effect and can cause a reduction in arterial
ressure; this is more prominent with milrinone (132).
inally, the effects of dobutamine are blunted when the
atients are already on beta-blocker therapy (133).
Despite the clinical rationale for using inotropes for
he failing heart, clinical trials conducted in chronic heart
ailure demonstrated disappointing results, with inotropic
se significantly increasing mortality (134 –136). For
cute heart failure, the OPTIME-CHF (Outcomes of a
rospective Trial of Intravenous Milrinone for Exacer-
ations of Chronic Heart Failure) study compared 48-h
ntravenous infusion of milrinone with placebo in pa-
ients without absolute indication for inotropic therapy; silrinone was associated with increased morbidity and
imilar mortality rate compared with placebo (137). In
he PROMISE (Effects of Oral Milrinone on Mortality
n Severe Chronic Heart Failure) trial (136), 1,088 patients
ith severe chronic systolic heart failure were assigned to
ouble-blind treatment with 40-mg oral milrinone daily
r placebo, on top of conventional treatment including
igoxin, diuretics, and an angiotensin-converting enzyme
nhibitor. Despite its beneficial hemodynamic actions, long-
erm therapy with oral milrinone increased the morbidity
nd mortality of patients with severe chronic systolic heart
ailure. Likewise, the ADHERE (Acute Decompensated
eart Failure National Registry) database (138) showed a
orse clinical course in acute heart failure patients receiving
notropes compared to vasodilators. In accordance with
hese findings, inotrope use should only be considered for
he subgroup of acute heart failure patients with clinically
vident hypoperfusion or shock, or as a bridge to more
efinitive treatment, such as revascularization or cardiac
ransplantation. However, this subgroup represents the
inority of those with acute heart failure (10%).
ombined SNS inhibition and stimulation. Combined
eta1-inhibition with beta2-stimulation with clenbuterol has
een proposed as a treatment modality to achieve sustained
eversal of severe heart failure in selected patients requiring
eft ventricular assist devices (139). The rationale for this
pproach was based on experimental studies demonstrating
hat clenbuterol treatment, alone or in combination with
echanical unloading, improved left ventricular function
t the whole-heart and cellular levels by affecting cell
orphology, excitation-contraction coupling, and myo-
lament sensitivity to calcium (140). After optimization
f medical therapy and achieving a constant left ventric-
lar size for at least 2 weeks, clenbuterol was adminis-
ered at an initial dose of 40 g twice daily, then at a dose
f 40 g 3 times daily, and finally at a dose of 700 g 3
imes daily. The dose was adjusted to maintain resting
eart rate at a level below 100 beats/min. Prior to clenbuterol
nitiation, carvedilol was replaced by the selective beta1-blocker
isoprolol.
It should be taken into consideration, however, that in a
ecent small, randomized controlled study, clenbuterol use
n patients with chronic heart failure was associated with a
ignificant increase in both lean mass and lean/fat ratio as
ell as in muscle strength, and a decrease in exercise
uration (141). Thus, the effectiveness of clenbuterol in
eart failure patients should be further evaluated in larger
rospective trials.
xercise. Exercise intolerance is a characteristic of patients
ith chronic heart failure, and skeletal myopathy contrib-
tes to the limitation of functional capacity in heart failure
142). SNS activation and myogenic reflex engagement
oderate the heart and muscle vasculature to maintain
dequate blood pressure during exercise (143). However,
ympathetic overactivity contributes to the skeletal myop-
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November 3, 2009:1747–62 Sympathetic Nervous System in Heart Failurethy seen in heart failure, because SNS-mediated vasocon-
triction at rest and during exercise restrains muscle blood
ow, arteriolar dilation, and capillary recruitment, leading to
nderperfusion, ischemia, release of reactive oxygen species,
nd chronic inflammation (144). Due to the presence of
xercise intolerance, heart failure patients are often coun-
eled to limit their physical activity. However, this advice
ay be inappropriate, because current evidence suggests
hat exercise training improves central hemodynamics, pe-
ipheral muscle function, and symptoms and reduces sym-
athetic activity even in patients treated with beta-blockers
145,146). The HF-ACTION (Heart Failure–A random-
zed Controlled Trial Investigating Outcomes of exercise
raiNing) study (147), the first large, randomized, controlled
rial to evaluate the effects of exercise training in heart
ailure patients, demonstrated that exercise training is safe
nd offers clinical benefits in this patient population. Spe-
ifically, exercise training was associated with an 11%
eduction in all-cause mortality or hospitalization, a 9%
eduction in cardiovascular mortality or cardiovascular hos-
italization, and a 15% reduction in cardiovascular mortality
r heart failure hospitalization. The mechanisms for these
eneficial effects of exercise in heart failure patients pro-
osed include: 1) improvement in arterial and chemoreflex
ontrol; 2) significant reduction in central sympathetic
utflow; 3) correction of central nervous system abnormal-
ties; 4) increase in peripheral blood flow; 5) reduction of
irculating cytokines; and 6) increase in muscle mass (148).
ecent experimental evidence suggests that the exercise
raining-induced beneficial effects on autonomic activity in
eart failure may be due to an up-regulation in central
ntioxidative mechanisms and suppressed central pro-
xidant mechanisms (149).
arasympathetic modulation. There is a complex, often
ntagonistic, interaction between the parasympathetic ner-
ous system and the SNS mediated partially by the second
essenger’s cAMP and cyclic guanosine monophosphate.
ndeed, vagus nerve afferent activation, originating periph-
rally, can modulate efferent sympathetic and parasympa-
hetic function centrally and at the baroreceptor level.
oreover, efferent vagus nerve activation can have tonic and
asal effects that inhibit sympathetic activation and release
f NE at the pre-synaptic level. Cardiovascular effects of
arasympathetic activation include heart rate reduction
indirectly by inhibition of the SNS and directly by hyper-
olarization of sinus node cells) and vasorelaxation (through
itric oxide synthesis) or vasoconstriction (direct activation
f smooth muscle) (150). The activity and physiological
ffects of the parasympathetic nervous system are attenuated
n heart failure, including lack of attenuation of SNS activity
151). Clinical and experimental data suggest that beta-
lockade in heart failure can augment reflex vagus nerve
ontrol of heart rate, by blocking cardiac sympathetic
re-junctional beta2-AR that facilitate NE release (152),
nd by increasing the density of M2 receptors, especially in
ndocardial tissues of the left ventricle free wall (153), sesulting in improved heart rate variability measurements
154). Finally, there are experimental studies that suggest
hat repeated exposure with a nicotinic agonist during the
evelopment of heart failure results in not only preserved
ut also supranormal effects of parasympathetic stimulation
n the sinus node and that vagus nerve stimulation therapy,
hen combined with chronic beta-blockade, elicits an
mprovement in left ventricular function and remodeling
hat is additive to that achieved with beta-blockade alone
155,156).
ther treatment modalities. DIGOXIN. Digoxin increases
ardiac contractility in heart failure patients by reversibly
nhibiting the alpha subunit of the sodium-potassium ATPase,
educing the transmembrane sodium gradient and indirectly
nhibiting the sodium-calcium exchanger. Thus, it allows
alcium to accumulate in cardiac myocytes and be taken up
y the sarcoplasmic reticulum (157). In addition, digoxin
mproves baroreceptor function, decreases sympathetic tone,
nd increases parasympathetic tone, favorably influencing
utonomic balance in heart failure (158–160). In heart
ailure patients with atrial fibrillation, the combination of
igoxin and a beta-blocker controls heart rate, and for heart
ailure patients in sinus rhythm, digoxin should be consid-
red as an adjunct therapy for uncontrolled symptomatology
161).
OSITIVE AIRWAY PRESSURE. Continuous or bi-level pos-
tive airway pressure has been employed for the treatment
f obstructive or central sleep apneas, which are highly
revalent in heart failure. Obstructive sleep apnea may
ffect heart failure through mechanical, adrenergic, and
ascular mechanisms, whereas central sleep apnea likely
rises as a consequence of heart failure (162,163). Treat-
ent of heart failure patients with coexisting obstructive
leep apnea by continuous positive airway pressure im-
roves baroreflex sensitivity during wakefulness, aug-
ents left ventricular ejection fraction, and lowers blood
ressure and heart rate (164). The result may be even
etter with the use of bi-level positive airway pressure
165). Evidence also supports the use of positive airway
ressure for improving several parameters of cardiovas-
ular function in heart failure patients with coexisting
entral sleep apnea. Studies in this patient population
ave shown that continuous positive airway pressure
ttenuates central sleep apnea, improves nocturnal oxy-
enation, increases left ventricular ejection fraction, low-
rs NE levels, and increases the 6-min walking distance
166). Moreover, its early institution reduces the fre-
uency of central sleep apnea episodes and may prolong
eart transplant-free survival (167).
onclusions
he role of activated SNS in maintaining hemodynamic
tability in the face of acute injury to the cardiovascular
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Sympathetic Nervous System in Heart Failure November 3, 2009:1747–62ystem is well known. Similarly, its role in heart failure
rogression and the benefits of beta-blocker therapy are well
ocumented. Several newer developments related to the
NS are at various stages of research and clinical applica-
ion. Genetic polymorphisms in the ARs may prove to be
ne of the earliest clinical applications for personalized
edicine, both in terms of risk prediction, and pharmacog-
nomic application and drug response. There has been a
rowing interest in the use of SNS activity assessment by
23I-MIBG imaging leading to an ongoing clinical trial.
ole of alpha ARs in modulating cardiac function is
nfolding and has potential therapeutic applications. Newer
rugs that may modify the SNS, such as combined beta1-
nhibition and beta2-stimulation with clenbuterol has
parked interest in patients with advanced heart failure
equiring mechanical assist device support. Understanding
NS functioning in further details and its modulation will
ontinue to provide pathophysiologic and therapeutic in-
ights for heart failure management.
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niversity Hospital, 1365 Clifton Road, NE, Suite AT430,
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